Medical Department, Division of Nephrology and Internal Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
Lipid Clinic at the Interdisciplinary Metabolism Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
BMJ Open. 2019 Sep 3;9(9):e030097. doi: 10.1136/bmjopen-2019-030097.
The LipidCardio Study was established for in-depth analyses of cardiovascular risk factors, providing well-defined cardiovascular and metabolic phenotypes. In particular, the role of lipoproteins in the pathobiological process and treatment of cardiovascular disease (CVD) will be a main focus.
1005 individuals aged 21 years and older undergoing cardiac catheterisation during 17 months at a tertiary academic cardiology centre were enrolled (troponin-positive acute coronary syndrome was exclusion criterion). The baseline data not only contain detailed phenotyping, broad biochemical parameters, genetic data, but also standardised personal and family history, a screening test for cognitive impairment, pulse wave analysis and measurements of hand grip strength, among others. Blood samples were stored in a biobank for future analyses.
The mean age of the participants at enrolment was 70.9±11.1 years (70% male). Coronary angiography provided evidence of obstructive coronary artery disease (CAD) in 69.9% of participants. Those with evidence of CAD were significantly more likely to be male, inactive, diabetic and with a family history of CVD than participants without CAD.About 20% of patients had lipoprotein(a) (Lp(a)) concentrations above 106.9 nmol/L (fifth quintile). These patients had significantly increased odds of obstructive CAD compared with participants in quintiles 1-4 (crude OR 1.70, 95% CI 1.17 to 2.48, p=0.005). There was reasonable evidence that with increasing severity of CAD the odds of having elevated Lp(a) increased. We were able to replicate the established strong association between specified single nucleotide polymorphisms (SNPs) in the gene (rs10455872, rs3798220 and rs186696265) and the gene (rs7412), and the concentration of Lp(a), validating our phenotype database and biobank.
Mortality information will be obtained in 2 year intervals. Follow-up phone interviews will be conducted at 3 and 6 years after enrolment. We seek to cooperate with other researchers, for example, by sharing data and biobank samples.
脂质心脏研究旨在深入分析心血管危险因素，提供明确的心血管和代谢表型。特别是，脂蛋白在心血管疾病（CVD）的病理生物学过程和治疗中的作用将是一个主要关注点。
在 17 个月内，共有 1005 名年龄在 21 岁及以上的个体在一家三级学术心脏病中心接受了心脏导管检查（急性冠状动脉综合征伴肌钙蛋白升高为排除标准）。基线数据不仅包含详细的表型、广泛的生化参数、遗传数据，还包括标准化的个人和家族史、认知障碍筛查测试、脉搏波分析以及手握力测量等。血液样本储存在生物库中，以备将来分析。
参与者入组时的平均年龄为 70.9±11.1 岁（70%为男性）。冠状动脉造影显示 69.9%的参与者存在阻塞性冠状动脉疾病（CAD）。与无 CAD 的参与者相比，有 CAD 证据的参与者更有可能为男性、不活跃、患有糖尿病且有 CVD 家族史。约 20%的患者脂蛋白（a）（Lp（a））浓度高于 106.9 nmol/L（第五五分位数）。这些患者与五分位数 1-4 中的参与者相比，阻塞性 CAD 的可能性明显增加（未经调整的 OR 1.70，95%CI 1.17 至 2.48，p=0.005）。有合理的证据表明，随着 CAD 严重程度的增加，Lp（a）升高的可能性增加。我们能够复制在基因（rs10455872、rs3798220 和 rs186696265）和基因（rs7412）中指定的单核苷酸多态性（SNP）与 Lp（a）浓度之间的既定强关联，验证了我们的表型数据库和生物库。
将每两年获得一次死亡率信息。在入组后 3 年和 6 年进行随访电话访谈。我们寻求与其他研究人员合作，例如通过共享数据和生物库样本。
